|
1
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ljungberg B, Campbell SC, Choi HY, Jacqmin
D, Lee JE, Weikert S and Kiemeney LA: The epidemiology of renal
cell carcinoma. Eur Urol. 60:615–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sjölund J, Johansson M, Manna S, Norin C,
Pietras A, Beckman S, Nilsson E, Ljungberg B and Axelson H:
Suppression of renal cell carcinoma growth by inhibition of Notch
signaling in vitro and in vivo. J Clin Invest. 118:217–228. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Athar U and Gentile TC: Treatment options
for metastatic renal cell carcinoma: A review. Can J Urol.
15:3954–3966. 2008.PubMed/NCBI
|
|
5
|
Randall JM, Millard F and Kurzrock R:
Molecular aberrations, targeted therapy, and renal cell carcinoma:
Current state-of-the-art. Cancer Metastasis Rev. 33:1109–1124.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Holland WS, Tepper CG, Pietri JE, Chinn
DC, Gandara DR, Mack PC and Lara PN Jr: Evaluating rational
non-cross-resistant combination therapy in advanced clear cell
renal cell carcinoma: Combined mTOR and AKT inhibitor therapy.
Cancer Chemother Pharmacol. 69:185–194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ramp U, Caliskan E, Mahotka C, Krieg A,
Heikaus S, Gabbert HE and Gerharz CD: Apoptosis induction in renal
cell carcinoma by TRAIL and gamma-radiation is impaired by
deficient caspase-9 cleavage. Br J Cancer. 88:1800–1807. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu WK, Wang XJ, Cheng AS, Luo MX, Ng SS,
To KF, Chan FK, Cho CH, Sung JJ and Yu J: Dysregulation and
crosstalk of cellular signaling pathways in colon carcinogenesis.
Crit Rev Oncol Hematol. 86:251–277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bolós V, Grego-Bessa J and de la Pompa JL:
Notch signaling in development and cancer. Endocr Rev. 28:339–363.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Z, Li Y, Ahmad A, Banerjee S, Azmi
AS, Kong D, Wojewoda C, Miele L and Sarkar FH: Down-regulation of
Notch-1 is associated with Akt and FoxM1 in inducing cell growth
inhibition and apoptosis in prostate cancer cells. J Cell Biochem.
112:78–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ai Q, Ma X, Huang Q, Liu S, Shi T, Zhang
C, Zhu M, Zhang Y, Wang B, Ni D, et al: High-level expression of
Notch1 increased the risk of metastasis in T1 stage clear cell
renal cell carcinoma. PLoS One. 7:e350222012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu S, Ma X, Ai Q, Huang Q, Shi T, Zhu M,
Wang B and Zhang X: NOTCH1 functions as an oncogene by regulating
the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma. Urol
Oncol. 31:938–948. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Terrone C, Cracco C, Porpiglia F, Bollito
E, Scoffone C, Poggio M, Berruti A, Ragni F, Cossu M, Scarpa RM and
Rossetti SR: Reassessing the current TNM lymph node staging for
renal cell carcinoma. Eur Urol. 49:324–331. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wan F, Zhu Y, Han C, Xu Q, Wu J, Dai B,
Zhang H, Shi G, Gu W and Ye D: Identification and validation of an
eight-gene expression signature for predicting high Fuhrman grade
renal cell carcinoma. Int J Cancer. 140:1199–1208. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai L, Ma X, Huang Y, Zou Y and Chen X:
Aberrant histone methylation and the effect of Suv39H1 siRNA on
gastric carcinoma. Oncol Rep. 31:2593–2600. 2014.PubMed/NCBI
|
|
16
|
Masuda S, Kumano K, Shimizu K, Imai Y,
Kurokawa M, Ogawa S, Miyagishi M, Taira K, Hirai H and Chiba S:
Notch1 oncoprotein antagonizes TGF-beta/Smad-mediated cell growth
suppression via sequestration of coactivator p300. Cancer Sci.
96:274–282. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Amarzguioui M and Prydz H: An algorithm
for selection of functional siRNA sequences. Biochem Biophys Res
Commun. 316:1050–1058. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ui-Tei K, Naito Y, Takahashi F, Haraguchi
T, Ohki-Hamazaki H, Juni A, Ueda R and Saigo K: Guidelines for the
selection of highly effective siRNA sequences for mammalian and
chick RNA interference. Nucleic Acids Res. 32:936–948. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reynolds A, Leake D, Boese Q, Scaringe S,
Marshall WS and Khvorova A: Rational siRNA design for RNA
interference. Nat Biotechnol. 22:326–330. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Inoki K, Corradetti MN and Guan KL:
Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet.
37:19–24. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vano YA, Tartour E, Fournier LS,
Beuselinck B, Mejean A and Oudard S: Prognostic factors in patients
with advanced renal cell carcinoma treated with VEGF-targeted
agents. Expert Rev Anticancer Ther. 14:523–542. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maillard I and Pear WS: Notch and cancer:
Best to avoid the ups and downs. Cancer Cell. 3:203–205. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yao J, Zheng K, Li C, Liu H and Shan X:
Interference of Notch1 inhibits the growth of glioma cancer cells
by inducing cell autophagy and down-regulation of Notch1-Hes-1
signaling pathway. Med Oncol. 32:6102015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grabher C, von Boehmer H and Look AT:
Notch 1 activation in the molecular pathogenesis of T-cell acute
lymphoblastic leukaemia. Nat Rev Cancer. 6:347–359. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kunnimalaiyaan S, Trevino J, Tsai S,
Gamblin TC and Kunnimalaiyaan M: Xanthohumol-mediated suppression
of Notch1 signaling is associated with antitumor activity in human
pancreatic cancer cells. Mol Cancer Ther. 14:1395–1403. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen C, Cui J, Zhang W and Shen P:
Robustness analysis identifies the plausible model of the Bcl-2
apoptotic switch. FEBS Lett. 581:5143–5150. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao N, Guo Y, Zhang M, Lin L and Zheng Z:
Akt-mTOR signaling is involved in Notch-1-mediated glioma cell
survival and proliferation. Oncol Rep. 23:1443–1447.
2010.PubMed/NCBI
|
|
28
|
Sangphech N, Osborne BA and Palaga T:
Notch signaling regulates the phosphorylation of Akt and survival
of lipopolysaccharide-activated macrophages via regulator of G
protein signaling 19 (RGS19). Immunobiology. 219:653–660. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pugazhenthi S, Nesterova A, Sable C,
Heidenreich KA, Boxer LM, Heasley LE and Reusch JE: Akt/protein
kinase B up-regulates Bcl-2 expression through cAMP-response
element-binding protein. J Biol Chem. 275:10761–10766. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Palomero T, Sulis ML, Cortina M, Real PJ,
Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, et
al: Mutational loss of PTEN induces resistance to NOTCH1 inhibition
in T-cell leukemia. Nat Med. 13:1203–1210. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cho D: Novel targeting of
phosphatidylinositol 3-kinase and mammalian target of rapamycin in
renal cell carcinoma. Cancer J. 19:311–315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bjornsti MA and Houghton PJ: The TOR
pathway: A target for cancer therapy. Nat Rev Cancer. 4:335–348.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mungamuri SK, Yang X, Thor AD and
Somasundaram K: Survival signaling by Notch1: Mammalian target of
rapamycin (mTOR)-dependent inhibition of p53. Cancer Res.
66:4715–4724. 2006. View Article : Google Scholar : PubMed/NCBI
|
